Clinical decision tools are needed to identify HIV-positive patients at high risk for poor outcomes after initiation of antiretroviral therapy
Margaret McNairy and colleagues highlight the need for clinical decision tools to help identify HIV patients who would benefit from tailored services to avoid poor outcomes such as death and loss to follow-up.
Vyšlo v časopise:
Clinical decision tools are needed to identify HIV-positive patients at high risk for poor outcomes after initiation of antiretroviral therapy. PLoS Med 14(4): e32767. doi:10.1371/journal.pmed.1002278
Kategorie:
Policy Forum
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.pmed.1002278
Souhrn
Margaret McNairy and colleagues highlight the need for clinical decision tools to help identify HIV patients who would benefit from tailored services to avoid poor outcomes such as death and loss to follow-up.
Zdroje
1. UNAIDS. UNAIDS Website. http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2015/july/20150714_PR_MDG6report. Geneva: UNAIDS; 2016 [Accessed 2016 May 24].
2. UNAIDS. 90-90-90 An Ambitious treatment target to help end the AIDS epidemic. http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf. Geneva: UNAIDS, 2014.
3. McNairy ML, El-Sadr WM. The HIV care continuum: no partial credit given. AIDS. 2012;26(14):1735–8. doi: 10.1097/QAD.0b013e328355d67b 22614888
4. The Global Fund. Differentiated care for HIV and Tuberculosis: A toolkit for health facilities. http://www.theglobalfund.org/documents/core/infonotes/Core_DifferentiatedCare_Toolkit_en/ Geneva: The Global Fund; 2016 [Accessed 2016 May 8].
5. WHO. HIV Treatment and Care, What's New in Service Delivery Fact Sheet. http://apps.who.int/iris/bitstream/10665/204461/1/WHO_HIV_2015.46_eng.pdf?ua=1. Geneva: WHO; 2015 [Accessed 2015 November 20].
6. Ellman T. Demedicalizing AIDS prevention and treatment in Africa. N Engl J Med. 2015;372(4):303–5. doi: 10.1056/NEJMp1414730 25607425
7. Decroo T, Koole O, Remartinez D, dos Santos N, Dezembro S, Jofrisse M, et al. Four-year retention and risk factors for attrition among members of community ART groups in Tete, Mozambique. Trop Med Int Health. 2014;19(5):514–21. doi: 10.1111/tmi.12278 24898272
8. Tsondai P WL, Grimsrud A, Mdlalo P, Trivino A, Boulle A. High rates of retention and viral suppression in the scale-up of antiretroviral therapy adherence clubs in Cape Town, South Africa. 21st International AIDS Conference; July 18–22, 2016; Durban, South AFrica 2016.
9. Grimsrud A, Lesosky M, Kalombo C, Bekker LG, Myer L. Implementation and Operational Research: Community-Based Adherence Clubs for the Management of Stable Antiretroviral Therapy Patients in Cape Town, South Africa: A Cohort Study. J Acquir Immune Defic Syndr. 2016;71(1):e16–23. doi: 10.1097/QAI.0000000000000863 26473798
10. Koenig SP, Rodriguez LA, Bartholomew C, Edwards A, Carmichael TE, Barrow G, et al. Long-term antiretroviral treatment outcomes in seven countries in the Caribbean. J Acquir Immune Defic Syndr. 2012;59(4):e60–71. doi: 10.1097/QAI.0b013e318245d3c1 22240464
11. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2008;22(15):1897–908. doi: 10.1097/QAD.0b013e32830007cd 18784453
12. McNairy ML, Lamb MR, Abrams EJ, Elul B, Sahabo R, Hawken MP, et al. Use of a Comprehensive HIV Care Cascade for Evaluating HIV Program Performance: Findings From 4 Sub-Saharan African Countries. J Acquir Immune Defic Syndr. 2015;70(2):e44–51. doi: 10.1097/QAI.0000000000000745 26375466
13. McNairy ML, Lamb MR, Carter RJ, Fayorsey R, Tene G, Mutabazi V, et al. Retention of HIV-infected children on antiretroviral treatment in HIV care and treatment programs in Kenya, Mozambique, Rwanda, and Tanzania. J Acquir Immune Defic Syndr. 2013;62(3):e70–81. doi: 10.1097/QAI.0b013e318278bcb0 23111575
14. Lawn SD, Harries AD. Reducing tuberculosis-associated early mortality in antiretroviral treatment programmes in sub-Saharan Africa. AIDS. 2011;25(12):1554–5; author reply 6. doi: 10.1097/QAD.0b013e328348fb61 21747238
15. Liechty CA, Solberg P, Were W, Ekwaru JP, Ransom RL, Weidle PJ, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health. 2007;12(8):929–35. doi: 10.1111/j.1365-3156.2007.01874.x 17697087
16. Fenner L, Brinkhof MW, Keiser O, Weigel R, Cornell M, Moultrie H, et al. Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa. J Acquir Immune Defic Syndr. 2010;54(5):524–32. doi: 10.1097/QAI.0b013e3181e0c4cf 20588185
17. Fox MP, Rosen S. Retention of Adult Patients on Antiretroviral Therapy in Low- and Middle-Income Countries: Systematic Review and Meta-analysis 2008–2013. J Acquir Immune Defic Syndr. 2015;69(1):98–108. doi: 10.1097/QAI.0000000000000553 25942461
18. Machine EM, Gillespie SL, Homedes N, Selwyn BJ, Ross MW, Anabwani G, et al. Lost to follow-up: failure to engage children in care in the first three months of diagnosis. AIDS Care. 2016;28(11):1402–10. doi: 10.1080/09540121.2016.1179714 27160542
19. Wilkinson LS, Skordis-Worrall J, Ajose O, Ford N. Self-transfer and mortality amongst adults lost to follow-up in ART programmes in low- and middle-income countries: systematic review and meta-analysis. Trop Med Int Health. 2015;20(3):365–79. doi: 10.1111/tmi.12434 25418366
20. Lahuerta M, Wu Y, Hoffman S, Elul B, Kulkarni SG, Remien RH, et al. Advanced HIV disease at entry into HIV care and initiation of antiretroviral therapy during 2006–2011: findings from four sub-saharan African countries. Clin Infect Dis. 2014;58(3):432–41. doi: 10.1093/cid/cit724 24198226
21. Braitstein P, Songok J, Vreeman RC, Wools-Kaloustian KK, Koskei P, Walusuna L, et al. "Wamepotea" (they have become lost): outcomes of HIV-positive and HIV-exposed children lost to follow-up from a large HIV treatment program in western Kenya. J Acquir Immune Defic Syndr. 2011;57(3):e40–6. doi: 10.1097/QAI.0b013e3182167f0d 21407085
22. WHO. World Health Organization/International Society of Hypertension risk prediction chart for cardiovascular disease. http://www.who.int/cardiovascular_diseases/guidelines/Chart_predictions/en/. Geneva: WHO/ISH; 2007 [Accessed 2016 May 6].
23. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243–50. doi: 10.1056/NEJM199701233360402 8995086
24. Quinn J, McDermott D, Stiell I, Kohn M, Wells G. Prospective validation of the San Francisco Syncope Rule to predict patients with serious outcomes. Annals of emergency medicine. 2006;47(5):448–54. doi: 10.1016/j.annemergmed.2005.11.019 16631985
25. Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, et al. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS. 2013;27(4):563–72. doi: 10.1097/QAD.0b013e32835b8c7f 23095314
26. Robbins GK, Johnson KL, Chang Y, Jackson KE, Sax PE, Meigs JB, et al. Predicting virologic failure in an HIV clinic. Clin Infect Dis. 2010;50(5):779–86. doi: 10.1086/650537 20121574
27. Mocroft A, Ledergerber B, Zilmer K, Kirk O, Hirschel B, Viard JP, et al. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. AIDS. 2007;21(14):1867–75. doi: 10.1097/QAD.0b013e328270b877 17721094
28. Boulle A, Schomaker M, May MT, Hogg RS, Shepherd BE, Monge S, et al. Mortality in patients with HIV-1 infection starting antiretroviral therapy in South Africa, Europe, or North America: a collaborative analysis of prospective studies. PLoS Med. 2014;11(9):e1001718. doi: 10.1371/journal.pmed.1001718 25203931
29. Amuron B, Namara G, Birungi J, Nabiryo C, Levin J, Grosskurth H, et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health. 2009;9:290. doi: 10.1186/1471-2458-9-290 19671185
30. Etard J-F, Ndiaye I, Thierry-Mieg M, Guèye NFN, Guèye PM, Lanièce I, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006;20(8):1181–9. doi: 10.1097/01.aids.0000226959.87471.01 16691070
31. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis. 2006;43(6):770–6. doi: 10.1086/507095 16912954
32. Koenig SP, Bernard D, Devieux JG, Atwood S, McNairy ML, Severe P, et al. Trends in CD4 Count Testing, Retention in Pre-ART Care, and ART Initiation Rates over the First Decade of Expansion of HIV Services in Haiti. PLoS ONE. 2016;11(2):e0146903. doi: 10.1371/journal.pone.0146903 26901795
33. Rachlis B, Ochieng D, Geng E, Rotich E, Ochieng V, Maritim B, et al. Implementation and operational research: evaluating outcomes of patients lost to follow-up in a large comprehensive care treatment program in western Kenya. J Acquir Immune Defic Syndr. 2015;68(4):e46–55. doi: 10.1097/QAI.0000000000000492 25692336
34. Brennan AT, Maskew M, Sanne I, Fox MP. The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa. J Int AIDS Soc. 2010;13:49. doi: 10.1186/1758-2652-13-49 21134297
35. Wijeysundera DN. Predicting outcomes: Is there utility in risk scores? Canadian Journal of Anesthesia/Journal canadien d'anesthésie. 2016;63(2):148–58. doi: 10.1007/s12630-015-0537-2 26670801
36. Reilly BM, Evans AT. Translating clinical research into clinical practice: impact of using prediction rules to make decisions. Ann Intern Med. 2006;144(3):201–9. 16461965
37. Toll BA, Katulak NA, Williams-Piehota P, O'Malley S. Validation of a scale for the assessment of food cravings among smokers. Appetite. 2008;50(1):25–32. doi: 10.1016/j.appet.2007.05.001 17574300
38. Hakim VM J., Szubert A.J., Siika A., Mallewa J., Agutu C., Pett S.L., Bwakura-Dangarembizi M., Lugemwa A., Kaunda S., Karoney M., Maitland K., Griffiths A., Kityo C., Mugyenyi P., Prendergast A.J., Walker A.S., Gibb D.M., REALITY Trial Team. Enhanced infection prophylaxis reduces mortality in severely immunosuppressed HIV-infected adults and older children initiating antiretroviral therapy in Kenya, Malawi, Uganda and Zimbabwe: the REALITY trial. AIDS 2016; Durban, South Africa2016.
39. Mfinanga S, Chanda D, Kivuyo SL, Guinness L, Bottomley C, Simms V, et al. Cryptococcal meningitis screening and community-based early adherence support in people with advanced HIV infection starting antiretroviral therapy in Tanzania and Zambia: an open-label, randomised controlled trial. Lancet. 2015;385(9983):2173–82. doi: 10.1016/S0140-6736(15)60164-7 25765698
40. McNairy ML, Gachuhi AB, Lamb MR, Nuwagaba-Biribonwoha H, Burke S, Ehrenkranz P, et al. The Link4Health study to evaluate the effectiveness of a combination intervention strategy for linkage to and retention in HIV care in Swaziland: protocol for a cluster randomized trial. Implementation science: IS. 2015;10:101. doi: 10.1186/s13012-015-0291-4 26189154
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2017 Číslo 4
- Statinová intolerance
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Metamizol v liečbe pooperačnej bolesti u detí do 6 rokov veku
- Co dělat při intoleranci statinů?
Najčítanejšie v tomto čísle
- Talking sensibly about depression
- A new cascade of HIV care for the era of “treat all”
- Fresh fruit consumption in relation to incident diabetes and diabetic vascular complications: A 7-y prospective study of 0.5 million Chinese adults
- Implementation science: Relevance in the real world without sacrificing rigor